Current report No. 2/2022 – Obtaining information concerning a European patent for esketamine inhalation formulation and expanding patent protection beyond the treatment of treatment-resistant depression

Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) – inside information.

January 11, 2021, 08:46 PM

In reference to current report No. 52/2021, the Management Board of Celon Pharma S.A. (“Company”) hereby informs that on January 10, 2022 it received specifications of European patents No. EP 3 731 815 B1 and EP 3 505 157 B1 for esketamine inhalation formulation, the granting of which was announced in “European Patent Bulletin 21/49” of December 8, 2021.

In accordance with the received specification, Patent No. EP 3 731 815 B1 concerns a pharmaceutical composition in the form of a dry powder, containing ketamine or its pharmaceutically acceptable salt, to be used to treat depression by direct pulmonary administration, whereas the scope of Patent EP 3 505 157 B1 is broader and involves using a pharmaceutical composition in the form of a dry powder, containing ketamine or its pharmaceutically acceptable salt, in a drug suitable for pulmonary administration, without being restricted solely to the treatment of treatment-resistant depression.
It might create possibilities for using it in developing drugs for other indications in this therapeutic area.
In the opinion of the Management Board, such a broad patent protection increases the value of potential commercialization of the Company’s products within the therapeutic areas covered by the protection.